4-(嘧啶-2-基氨基)苯甲酸 | 920287-46-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(嘧啶-2-基氨基)苯甲酸
• 英文名称: 4-(pyrimidin-2-ylamino)benzoic acid
• CAS: 920287-46-3
• 化学式: C₁₁H₉N₃O₂
• mdl: MFCD09909722
• 分子量: 215.211
• InChiKey: ZBDXNIXEOKDJKQ-UHFFFAOYSA-N

物化性质

• 沸点：
  453.1±47.0 °C(Predicted)
• 密度：
  1.393±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.1
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 海关编码：
  2933599090

反应信息

• 作为反应物：
  描述：

  4-(嘧啶-2-基氨基)苯甲酸 在 氯化亚砜 作用下， 生成 4-(pyrimidin-2-ylamino)benzoyl chloride
  参考文献：
  名称：

  Pyrimidine benzamide-based thrombopoietin receptor agonists

  摘要：

  A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by replacing the thiazole with a thiadiazole. Potency in the series was improved by modifying the substituents on the pyrimidine and/or on the thiazole or thiadiazole pendant aryl ring. In vivo examination revealed that compounds from the series are not highly bioavailable. This is attributed to low solubility and poor permeability. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.038
• 作为产物：
  描述：

  Tert-butyl 4-[(pyrimidin-2-yl)amino]benzoate 在 三氟乙酸 作用下， 生成 4-(嘧啶-2-基氨基)苯甲酸
  参考文献：
  名称：

  Pyrimidine benzamide-based thrombopoietin receptor agonists

  摘要：

  A series of pyrimidine benzamide-based thrombopoietin receptor agonists is described. The lead molecule contains a 2-amino-5-unsubstituted thiazole, a group that has been associated with idiosyncratic toxicity. The potential for metabolic oxidation at C-5 of the thiazole, the likely source of toxic metabolites, was removed by substitution at C-5 or by replacing the thiazole with a thiadiazole. Potency in the series was improved by modifying the substituents on the pyrimidine and/or on the thiazole or thiadiazole pendant aryl ring. In vivo examination revealed that compounds from the series are not highly bioavailable. This is attributed to low solubility and poor permeability. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.07.038

文献信息

• Glutamate aggrecanase inhibitors
  申请人：Sum Phaik-Eng

  公开号：US20070043066A1

  公开（公告）日：2007-02-22

  The present invention relates to modulators of metalloproteinase activity.

  本发明涉及金属蛋白酶活性调节剂。
• Site-selective C–H activation and regiospecific annulation using propargylic carbonates
  作者：Qingquan Lu、Shobhan Mondal、Sara Cembellín、Steffen Greßies、Frank Glorius

  DOI：10.1039/c9sc01703h

  日期：——

  The weakly coordinating carboxylic acid moiety outperformed other typically used directing groups in C–H activation, including ketone, nitrile, sulfonamide, amide and strongly coordinating nitrogen heterocycles. This is an important step towards the application of C–H activation reactions in complex (functional) real-world molecules.

  在本文中，我们描述了空前的Ru II催化的苯甲酸与炔丙基碳酸酯的Ru II催化位点选择性和区域专一性的环化反应。在CH活化中，弱配位的羧酸部分优于其他常用的指导基团，包括酮，腈，磺酰胺，酰胺和强配氮杂环。这是在复杂的（功能性）现实世界分子中应用C–H活化反应的重要一步。
• GLUTAMATE AGGRECANASE INHIBITORS
  申请人：Sum Phaik-Eng

  公开号：US20100010012A1

  公开（公告）日：2010-01-14

  The present invention relates to modulators of metalloproteinase activity.

  本发明涉及金属蛋白酶活性调节剂。
• WO2020036940A5
  申请人：——

  公开号：WO2020036940A5

  公开（公告）日：2022-06-21
• US7553873B2
  申请人：——

  公开号：US7553873B2

  公开（公告）日：2009-06-30